A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.

Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Seppi K, Monnet A, Shariati N, Ricci B, Rutten-Jacobs L, Respondek G, Kustermann T, Taylor KI, Trundell D, Fontoura P, Doody R, Svoboda H, Bonni A, PADOVA Investigators and Prasinezumab Study Group

Open source

DOI: 10.1016/j.parkreldis.2024.107257
Published: 2025 Mar
Container: Parkinsonism & related disorders
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.parkreldis.2024.107257,
  title = {A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.},
  author = {Nikolcheva T and Pagano G and Pross N and Simuni T and Marek K and Postuma RB and Pavese N and Stocchi F and Seppi K and Monnet A and Shariati N and Ricci B and Rutten-Jacobs L and Respondek G and Kustermann T and Taylor KI and Trundell D and Fontoura P and Doody R and Svoboda H and Bonni A and PADOVA Investigators and Prasinezumab Study Group},
  year = {2025},
  journal = {Parkinsonism \& related disorders},
  doi = {10.1016/j.parkreldis.2024.107257},
  url = {https://doi.org/10.1016/j.parkreldis.2024.107257}
}

RIS

TY  - JOUR
TI  - A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
AU  - Nikolcheva T
AU  - Pagano G
AU  - Pross N
AU  - Simuni T
AU  - Marek K
AU  - Postuma RB
AU  - Pavese N
AU  - Stocchi F
AU  - Seppi K
AU  - Monnet A
AU  - Shariati N
AU  - Ricci B
AU  - Rutten-Jacobs L
AU  - Respondek G
AU  - Kustermann T
AU  - Taylor KI
AU  - Trundell D
AU  - Fontoura P
AU  - Doody R
AU  - Svoboda H
AU  - Bonni A
AU  - PADOVA Investigators and Prasinezumab Study Group
PY  - 2025
JO  - Parkinsonism & related disorders
DO  - 10.1016/j.parkreldis.2024.107257
UR  - https://doi.org/10.1016/j.parkreldis.2024.107257
ER  -

APA

T, N., G, P., N, P., T, S., K, M., RB, P., N, P., F, S., K, S., A, M., N, S., B, R., L, R., G, R., T, K., KI, T., D, T., P, F., R, D., H, S., A, B., & Group, P. I. A. P. S. (2025). A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.. Parkinsonism & related disorders. https://doi.org/10.1016/j.parkreldis.2024.107257

Source records

pubmed · retrieved 2026-09-26T02:53:00.015Z